Humanise an Internal Research Summary

Problem/Feature Description

A pharmaceutical research team used an AI tool to generate a first draft of an internal project summary — a document that will be circulated to senior leadership and external clinical partners. The document needs to sound like it was written by a human scientist, not a language model.

The team lead has given you the following constraints: all drug names, dosage figures, trial phase numbers, and dates must remain exactly as written — these are regulated facts and any change would be a compliance issue. The target register is formal-professional (the readers are MDs and research directors), and the document should remain as a single prose block in UK English with no bullet lists. No change log or edit summary is needed. The paragraph order must be preserved.

Rewrite the summary so it reads as a credible, professional document rather than AI-generated boilerplate, while strictly preserving all factual content.

Output Specification

Write the rewritten summary to rewritten_summary.txt. The file should contain only the rewritten text — nothing else.

Input Files

The following file is provided as input. Extract it before beginning.

=============== FILE: inputs/research_summary.txt =============== In today's rapidly evolving pharmaceutical landscape, our organisation stands at a pivotal moment — showcasing our unwavering commitment to innovation and underscoring the transformative potential of next-generation oncology therapeutics. The Phase II clinical trial of Veralinib 200mg, initiated in March 2023, serves as a testament to our dedication to fostering advances in targeted cancer therapy.

The trial — enrolling 240 patients across four UK sites — has demonstrated promising preliminary results. Additionally, interim data collected through December 2023 showcases a 34% reduction in tumour burden among evaluable patients, underscoring the compound's unique mechanism of action. Experts agree that targeted KRAS inhibition could potentially represent a paradigm shift in the treatment of non-small-cell lung cancer, and our findings are perfectly positioned to contribute meaningfully to this evolving field.

Due to the fact that regulatory submissions require comprehensive safety data, the full dataset — encompassing adverse event profiles, pharmacokinetic analyses, and biomarker correlations — will be finalised by Q3 2024. While challenges remain, the programme continues to thrive. In order to ensure alignment with our clinical partners, a steering committee meeting has been scheduled for 15 February 2024.